Immatics presented encouraging clinical data for its IMA402 PRAME bispecific and IMA203CD8 PRAME cell therapies at the 2026 ESMO Annual Meeting. IMA402 showed a 32% confirmed objective response rate (cORR) in advanced melanoma patients with high PRAME expression, with durable responses and a favorable safety profile. IMA203CD8 demonstrated a 55% cORR in heavily pretreated gynecologic cancer patients, also with manageable safety and durable anti-tumor activity across multiple tumor types. These results support further development of both therapies across various solid tumors, with ongoing trials and combination strategies planned to expand their clinical use.
Immatics' clinical data presentations on IMA402 and IMA203CD8 bispecific and cell therapies provide context for health-sector market activity. For readers following the health sector, here is Pluang's market snapshot as of Oct 24, 2026 11:31 WIB: Among 150 priced US health stocks, 44 rose and 105 fell. Notable movers include Inovio Pharmaceuticals Inc (INO) at USD 0.90 with a 6.94% increase and a nearly balanced Pluang order activity of 51% Sell / 49% Buy, Hims and Hers Health Inc (HIMS) at USD 27.71 down 4.87% with 74% Sell orders, and Amylx Pharmaceuticals Inc (AMLX) at USD 27.20 down 4.80%.
Anthropic reported a massive increase in revenue, reaching $16.3 billion in the first half of 2026 compared to just $1.1 billion in the same period last year. This surge highlights rapid growth and strong demand for its products or services. The dram...
Early Ethereum investors sold a total of 4,000 ETH from two wallets, with one ICO participant selling 1,000 ETH and another holder offloading 3,000 ETH worth $7.23 million. This activity coincides with Santiment's report of the largest daily net ETH ...
Eli Lilly's investigational drug sofetabart mipitecan (Sofe-M), combined with bevacizumab, achieved a 79% confirmed objective response rate and 100% disease control rate in a Phase 1 study involving platinum-sensitive ovarian cancer patients. The tre...
Zymeworks presented new Phase 1 data for ZW191, an antibody-drug conjugate targeting folate receptor alpha, showing a 64.5% confirmed response rate at the 6.4 mg/kg dose in heavily pretreated patients with platinum-resistant ovarian cancer. The treat...
Bitcoin's price fell below its 50-day moving average for the first time in 66 days, closing at $80,806, about 1.23% below the $81,807 average. This break is significant mainly for short-term trading algorithms rather than indicating a long-term trend...
